Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Daniela Galimberti & Elio Scarpini. (2016) Emerging amyloid disease-modifying drugs for Alzheimer’s disease. Expert Opinion on Emerging Drugs 21:1, pages 5-7.
Read now
Read now
Diana L Castillo-Carranza, Marcos J Guerrero-Muñoz & Rakez Kayed. (2014) Immunotherapy for the treatment of Alzheimer’s disease: amyloid-β or tau, which is the right target?. ImmunoTargets and Therapy 3, pages 19-28.
Read now
Read now
Dijana Novakovic, Marco Feligioni, Sergio Scaccianoce, Alessandra Caruso, Sonia Piccinin, Chiara Schepisi, Francesco Errico, Nicola B Mercuri, Ferdinando Nicoletti & Robert Nisticò. (2013) Profile of gantenerumab and its potential in the treatment of Alzheimer’s disease. Drug Design, Development and Therapy 7, pages 1359-1364.
Read now
Read now
Yun Li, Yahong Liu, Zhaojun Wang & Yongjun Jiang. (2013) Clinical trials of amyloid-based immunotherapy for Alzheimer's disease: end of beginning or beginning of end?. Expert Opinion on Biological Therapy 13:11, pages 1515-1522.
Read now
Read now
Haythum O Tayeb, Evan D Murray, Bruce H Price & Frank I Tarazi. (2013) Bapineuzumab and solanezumab for Alzheimer's disease: is the ‘amyloid cascade hypothesis' still alive?. Expert Opinion on Biological Therapy 13:7, pages 1075-1084.
Read now
Read now
Gabriel C Léger & Fadi Massoud. (2013) Novel disease-modifying therapeutics for the treatment of Alzheimer’s disease. Expert Review of Clinical Pharmacology 6:4, pages 423-442.
Read now
Read now
Kelly R Bales. (2012) The value and limitations of transgenic mouse models used in drug discovery for Alzheimer's disease: an update. Expert Opinion on Drug Discovery 7:4, pages 281-297.
Read now
Read now
Bruno P Imbimbo, Simone Ottonello, Vincenza Frisardi, Vincenzo Solfrizzi, Antonio Greco, Davide Seripa, Alberto Pilotto & Francesco Panza. (2012) Solanezumab for the treatment of mild-to-moderate Alzheimer’s disease. Expert Review of Clinical Immunology 8:2, pages 135-149.
Read now
Read now
Articles from other publishers (23)
Michael Kunle Ajenikoko, Abayomi Oyeyemi Ajagbe, Oluwanisola Akanji Onigbinde, Akeem Ayodeji Okesina & Ahmad Adekilekun Tijani. (2023) Review of Alzheimer’s disease drugs and their relationship with neuron-glia interaction. IBRO Neuroscience Reports 14, pages 64-76.
Crossref
Crossref
Parth Sharma, Ritchu Babbar, Twinkle Sharma, Piyush Madaan, Sandeep Arora & Vishnu Nayak Badavath. (2023) Anti-Amyloid-β Immunotherapy: A Leading Novel Avenue for Alzheimer's
Disease. Mini-Reviews in Medicinal Chemistry 23:1, pages 53-66.
Crossref
Crossref
Dylan Shea & Valerie Daggett. (2022) Amyloid-β Oligomers: Multiple Moving Targets. Biophysica 2:2, pages 91-110.
Crossref
Crossref
Liang Wang & Xiaobo Mao. (2021) Role of Retinal Amyloid-β in Neurodegenerative Diseases: Overlapping Mechanisms and Emerging Clinical Applications. International Journal of Molecular Sciences 22:5, pages 2360.
Crossref
Crossref
Luis O. Soto-Rojas, Mar Pacheco-Herrero, Paola A. Martínez-Gómez, B. Berenice Campa-Córdoba, Ricardo Apátiga-Pérez, Marcos M. Villegas-Rojas, Charles R. Harrington, Fidel de la Cruz, Linda Garcés-Ramírez & José Luna-Muñoz. (2021) The Neurovascular Unit Dysfunction in Alzheimer’s Disease. International Journal of Molecular Sciences 22:4, pages 2022.
Crossref
Crossref
Md. Sahab Uddin, Md. Tanvir Kabir, Md. Sohanur Rahman, Tapan Behl, Philippe Jeandet, Ghulam Md Ashraf, Agnieszka Najda, May N. Bin-Jumah, Hesham R. El-Seedi & Mohamed M. Abdel-Daim. (2020) Revisiting the Amyloid Cascade Hypothesis: From Anti-Aβ Therapeutics to Auspicious New Ways for Alzheimer’s Disease. International Journal of Molecular Sciences 21:16, pages 5858.
Crossref
Crossref
Laia Montoliu-Gaya & Sandra Villegas. (2018) Immunotherapy for neurodegenerative diseases: the Alzheimer's disease paradigm. Current Opinion in Chemical Engineering 19, pages 59-67.
Crossref
Crossref
Zhidong Liu, Aihua Zhang, Hui Sun, Ying Han, Ling Kong & Xijun Wang. (2017) Two decades of new drug discovery and development for Alzheimer's disease. RSC Advances 7:10, pages 6046-6058.
Crossref
Crossref
Laia Montoliu-Gaya & Sandra Villegas. (2016)
A
β
-Immunotherapeutic strategies: a wide range of approaches for Alzheimer's disease treatment
. Expert Reviews in Molecular Medicine 18.
Crossref
Crossref
Jennifer G Goldman, Neelum T Aggarwal & Cynthia D Schroeder. (2015) Mild cognitive impairment: an update in Parkinson's disease and lessons learned from Alzheimer's disease. Neurodegenerative Disease Management 5:5, pages 425-443.
Crossref
Crossref
Thomas A. Bayer. (2015) Proteinopathies, a core concept for understanding and ultimately treating degenerative disorders?. European Neuropsychopharmacology 25:5, pages 713-724.
Crossref
Crossref
Kenji Sakai, Delphine Boche, Roxana Carare, David Johnston, Clive Holmes, Seth Love & James A. R. Nicoll. (2014) A? immunotherapy for Alzheimer?s disease: effects on apoE and cerebral vasculopathy. Acta Neuropathologica 128:6, pages 777-789.
Crossref
Crossref
Erwin De Genst, Anne Messer & Christopher M. Dobson. (2014) Antibodies and protein misfolding: From structural research tools to therapeutic strategies. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics 1844:11, pages 1907-1919.
Crossref
Crossref
Haibin Liu, Lirong Wang, Weiwei Su & Xiang-Qun Xie. (2014) Advances in recent patent and clinical trial drug development for Alzheimer’s disease. Pharmaceutical Patent Analyst 3:4, pages 429-447.
Crossref
Crossref
Maria Serpente, Rossana Bonsi, Elio Scarpini & Daniela Galimberti. (2014) Innate Immune System and Inflammation in Alzheimer's Disease: From Pathogenesis to Treatment. Neuroimmunomodulation 21:2-3, pages 79-87.
Crossref
Crossref
Nady Braidy, Anne Poljak, Tharusha Jayasena & Perminder Sachdev. 2014. Handbook of Neurotoxicity. Handbook of Neurotoxicity
1173
1190
.
Ezio Giacobini & Gabriel Gold. (2013) Alzheimer disease therapy—moving from amyloid-β to tau. Nature Reviews Neurology 9:12, pages 677-686.
Crossref
Crossref
Nikolai Lorenzen, Erich E. Wanker & Daniel Otzen. 2013. Amyloid Fibrils and Prefibrillar Aggregates. Amyloid Fibrils and Prefibrillar Aggregates
345
372
.
Ingmar Skoog, Amos D. Korczyn & Alla Guekht. (2012) Neuroprotection in vascular dementia: A future path. Journal of the Neurological Sciences 322:1-2, pages 232-236.
Crossref
Crossref
W. Wang, L. Fan, D. Xu, Z. Wen, R. Yu & Q. Ma. (2012) Immunotherapy for Alzheimer's disease. Acta Biochimica et Biophysica Sinica 44:10, pages 807-814.
Crossref
Crossref
Remy Robert & Kim L. Wark. (2012) Engineered antibody approaches for Alzheimer?s disease immunotherapy. Archives of Biochemistry and Biophysics 526:2, pages 132-138.
Crossref
Crossref
Haythum O. Tayeb, Hyun Duk Yang, Bruce H. Price & Frank I. Tarazi. (2012) Pharmacotherapies for Alzheimer's disease: Beyond cholinesterase inhibitors. Pharmacology & Therapeutics 134:1, pages 8-25.
Crossref
Crossref
Francesco PanzaVincenza Frisardi, Vincenzo Solfrizzi, Bruno P Imbimbo, Giancarlo Logroscino, Andrea Santamato, Antonio Greco, Davide Seripa & Alberto Pilotto. (2012) Immunotherapy for Alzheimer’s disease: from anti-β-amyloid to tau-based immunization strategies. Immunotherapy 4:2, pages 213-238.
Crossref
Crossref